Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.927,45 +298,97 (+0,79%) EUR/USD
1,0735 +0,0002 (+0,02%) Bitcoin EUR
60.068,66 +167,66 (+0,28%) CMC Crypto 200
1.393,27 -3,26 (-0,23%)
Hercules Capital, Inc. (0J4M.L)
| Chiusura precedente | 18,91 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 3.126 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,32 |
| Rapporto PE (ttm) | 0,21 |
| EPS (ttm) | 0,91 |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireX4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The company also announced that it drew down $22.5 million upon the transaction’s closing. “This expanded loan facility creates significant financial flexibility for X4 a
GlobeNewswireCOMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the Company has entered into a term loan agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million. Kabir Nath, COMPASS Pathways Chief Executive Officer said, “COMPASS is pleased to partner with Hercules for this source of non-dilutive financing to support our COMP360 phas
